TY - JOUR
T1 - Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
AU - Kamata, Kazuhiro
AU - Jindai, Kazuaki
AU - Ichihara, Nao
AU - Saito, Hiroki
AU - Kato, Hideaki
AU - Kunishima, Hiroyuki
AU - Shintani, Ayumi
AU - Nishida, Osamu
AU - Fujitani, Shigeki
N1 - Funding Information:
All authors would like to acknowledge the following colleagues for their contribution to supporting the launch of REMAP-CAP in Japan: Professor Steve Webb, Mr. Cameron Green, Dr. Colin McArthur, Ms. Vanessa Singh, Dr. Srinivas Murthy, Dr. Abigail Beane, and Dr. Meredith Buxton. Shigeki Fujitani and Hiroki Saito represent the Infection Control Committee of the Japanese Society of Intensive Care Medicine, and appreciate the contribution of the other committee members to facilitating the collaboration with REMAP-CAP and the Japanese Society of Intensive Care Medicine.
Funding Information:
This work was supported by the Japan Agency for Medical Research and Development (19fk0108154s0201).
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.
AB - REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.
UR - http://www.scopus.com/inward/record.url?scp=85104402711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104402711&partnerID=8YFLogxK
U2 - 10.1186/s40560-021-00547-7
DO - 10.1186/s40560-021-00547-7
M3 - Letter
AN - SCOPUS:85104402711
VL - 9
JO - Journal of Intensive Care
JF - Journal of Intensive Care
SN - 2052-0492
IS - 1
M1 - 34
ER -